About the Project
Applications are invited for a 3.5 year fully funded PhD Studentship starting 25th September 2023
Treatment with antibodies that target one of the immune checkpoints have revolutionized cancer therapy. In the last decade use of these drugs has drastically improved survival in patients suffering from advanced lung and skin cancers. Immune checkpoint inhibitors work by reactivating the patient’s own immune response enabling immune cells to recognise and attack cancer cells. The major drawback of this type of cancer treatment is that in around one third of patients, the host immune response becomes overactive and starts to attack healthy normal tissues of the gut, skin, kidneys, and lungs. The resultant inflammation toxicity often means patients must stop treatment. These patients then don’t receive sufficient cancer treatment to halt the disease and in some patients the inflammation is so severe that it directly results in patient death.
Currently there is a lack of biomarkers to identify patients at risk of inflammation toxicity. We are aiming to use patient samples to identify genetic, cellular and tissue-based factors that are more common in patients who experience serious inflammation toxicity. We can then test for the presence of these before a patient is treated with immunotherapy. We can also design experiments to find out how these factors are involved in inflammation toxicity. Research we have already carried out identified an immune cell marker which, when absent in patients, results in inflammation toxicity. If successful, this project will enable us to identify patients at risk of inflammation toxicity and select specific treatments to ensure patients get the best possible cancer treatment. Currently inflammation toxicity puts a huge burden on NHS resources as well as contributing heavily to patient morbidity and mortality. Understanding, predicting, and preventing its occurrence is of vital importance.
Person Specification
We are seeking a talented and motivated student to join the Cancer Inflammation theme within the NIHR Biomedical Research Centre Birmingham. The Research Fellow will be supervised jointly by Professor Gary Middleton and Dr Claire Palles within the Institutes of Immunology and Immunotherapy (III) and Cancer and Genomic Sciences (ICGS) at the University of Birmingham.
Applicants should have a strong background in immunology, cancer and genetics. They should have a commitment to biomedical research and hold or realistically expect to obtain at least an Upper Second-Class Honours Degree in Biological Sciences, Biochemistry, Medical Sciences or similar. Laboratory, data analysis and statistical training will be provided but some experience is desirable.
How to apply
Applications should be directed to Claire Palles at c.palles@bham.ac.uk. To apply, please send:
· A Detailed CV, including your nationality and country of birth;
· Names and addresses of two referees;
· A covering letter highlighting your research experience/capabilities;
· Copies of your degree transcripts;
· Evidence of your proficiency in the English language, if applicable.
Applicants will be required to attend an interview. This can be conducted face –to –face, by telephone or skype




Reviews
There are no reviews yet.